Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 3,370.00
+85.00 (2.59%)
At close: Sep 9, 2026
Genome & Company Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 24,461 | 24,587 | 27,745 | 14,296 | 14,085 | 451.25 |
Other Revenue | 0 | - | -0 | - | -0 | - |
| 24,461 | 24,587 | 27,745 | 14,296 | 14,085 | 451.25 | |
Revenue Growth | 1.84% | -11.38% | 94.07% | 1.50% | 3021.27% | 199.67% |
Cost of Revenue | 11,130 | 11,181 | 12,075 | 10,232 | 8,487 | 77.01 |
Gross Profit | 13,331 | 13,406 | 15,670 | 4,064 | 5,598 | 374.24 |
Selling, General & Admin | 27,406 | 26,904 | 22,025 | 28,677 | 19,664 | 14,123 |
Research & Development | 11,707 | 11,948 | 13,379 | 25,666 | 36,793 | 21,263 |
Amortization of Goodwill & Intangibles | 2,142 | 2,509 | 2,855 | 2,851 | 4,763 | 761.51 |
Operating Expenses | 42,520 | 42,641 | 39,869 | 59,156 | 63,110 | 36,461 |
Operating Income | -29,189 | -29,234 | -24,199 | -55,092 | -57,512 | -36,087 |
Interest Expense | -4,185 | -4,720 | -3,541 | -1,738 | -175 | -54.92 |
Interest & Investment Income | 820.23 | 1,824 | 3,778 | 4,121 | 850.8 | 458.17 |
Currency Exchange Gain (Loss) | 586.25 | 236.18 | -52.4 | -40.56 | -29.46 | -468.02 |
Other Non Operating Income (Expenses) | -11,596 | 31,557 | 4,206 | 3,252 | -1,112 | 161.16 |
EBT Excluding Unusual Items | -37,487 | -337.15 | -19,808 | -49,499 | -57,979 | -35,991 |
Gain (Loss) on Sale of Investments | -1,248 | -583.4 | 40.28 | 46.44 | -54.79 | - |
Gain (Loss) on Sale of Assets | -96.9 | -76.89 | -79.51 | -77.11 | 0.69 | -12.93 |
Asset Writedown | -3,095 | -3,095 | -8,367 | -2,325 | - | - |
Other Unusual Items | -2,656 | -4,575 | - | - | - | - |
Pretax Income | -44,583 | -8,668 | -28,215 | -51,855 | -58,033 | -36,004 |
Income Tax Expense | -1,399 | -980.96 | -1,365 | -1,202 | -1,083 | - |
Earnings From Continuing Operations | -43,184 | -7,687 | -26,850 | -50,653 | -56,950 | -36,004 |
Minority Interest in Earnings | 1,822 | 1,259 | 6,737 | 3,187 | 5,112 | 1,887 |
Net Income | -41,361 | -6,428 | -20,112 | -47,466 | -51,838 | -34,117 |
Net Income to Common | -41,361 | -6,428 | -20,112 | -47,466 | -51,838 | -34,117 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 35 | 31 | 30 | 28 | 28 | 27 |
Shares Outstanding (Diluted) | 35 | 31 | 30 | 28 | 28 | 27 |
Shares Change | -8.79% | 2.75% | 7.91% | 0.32% | 4.71% | 39.60% |
EPS (Basic) | -1179.43 | -205.30 | -660.00 | -1680.81 | -1841.50 | -1269.10 |
EPS (Diluted) | -1179.43 | -205.30 | -660.00 | -1680.81 | -1841.50 | -1269.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -18,090 | -18,671 | -20,301 | -51,077 | -50,399 | -29,034 |
Free Cash Flow Per Share | -515.84 | -596.33 | -666.18 | -1808.70 | -1790.39 | -1080.03 |
Gross Margin | 54.50% | 54.53% | 56.48% | 28.43% | 39.74% | 82.94% |
Operating Margin | -119.33% | -118.90% | -87.22% | -385.37% | -408.34% | -7997.20% |
Profit Margin | -169.09% | -26.14% | -72.49% | -332.02% | -368.05% | -7560.62% |
Free Cash Flow Margin | -73.95% | -75.94% | -73.17% | -357.28% | -357.83% | -6434.20% |
EBITDA | -23,169 | -22,563 | -16,752 | -46,820 | -48,051 | -33,496 |
EBITDA Margin | -94.72% | -91.77% | -60.38% | - | - | - |
D&A For EBITDA | 6,020 | 6,672 | 7,447 | 8,272 | 9,462 | 2,591 |
EBIT | -29,189 | -29,234 | -24,199 | -55,092 | -57,512 | -36,087 |
EBIT Margin | -119.33% | -118.90% | -87.22% | - | - | - |
Advertising Expenses | - | 5,249 | 3,803 | 2,033 | 1,505 | 987.32 |